Article
Epistatic connectivity among HCV genomic sites as a genetic marker of interferon resistance.
Antiviral therapy - 1 Jan 2012
Lara James, Khudyakov Yury
Abstract excerpt
Until recently, the standard-of-care therapy of patients with HCV infection involves treatment with interferon (IFN) and ribavirin (RBV). Host demographic and genetic factors as well as HCV genetic heterogeneity have been shown to be associated with outcomes of therapy. Although resistance to IFN/RBV remains an important clinical and public health problem, there are no reliable genetic markers for the prediction...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
